Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
Abstract: Introduction Urothelial carcinomas are the most common types of bladder tumors that have recently shown a changing trend in treatment protocols with the introduction and approval of immune checkpoint inhibitors. The most important immune checkpoint lies with the PD-1–PD-L1 axis. Although multiple drugs have been approved, there is uncertainty about patient selection criteria and diagnostic assays. Recent studies related to the laboratory-developed tests have opened up the horizon of PD-1 and PD-L1 immunohistochemistry even at resource-constrained laboratories. We propose to study these immunohistochemistry markers in our laboratory using newer clones. Materials and Methods We selected 116 consecutive cases of transurethral bladder tumor resection from our laboratory archive and applied PD-1 and PD-L1 immunohistochemistry. The study was approved by the institution's ethics committee. Results We found high expression of PD-1 and PD-L1 in urothelial carcinoma even with different cut-offs of PD-L1. Muscle invasion, lamina invasion, and grade of carcinoma had a statistically significant effect on the expression; however, age and sex did not affect the expression. Conclusion Based on our current study, we can conclude that the clones used in our study show high expression in urothelial carcinoma and can aid in patient selection and treatment protocol, irrespective of age and sex.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas ; day:10 ; month:11 ; year:2021
Journal of laboratory physicians ; (10.11.2021)
- Beteiligte Personen und Organisationen
-
Kumar, Utpal
Anthony, Michael Leonard
Sahai, Rishabh
Mittal, Ankur
Durgapal, Prashant
Kishore, Sanjeev
- DOI
-
10.1055/s-0041-1736480
- URN
-
urn:nbn:de:101:1-2022031921162452031712
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kumar, Utpal
- Anthony, Michael Leonard
- Sahai, Rishabh
- Mittal, Ankur
- Durgapal, Prashant
- Kishore, Sanjeev
Ähnliche Objekte (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Molecular classification of high-grade, muscle-invasive urothelial carcinomas and the relationship with CTLA-4 and PD-L1 expression
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Molecular classification of high-grade, muscle-invasive urothelial carcinomas and the relationship with CTLA-4 and PD-L1 expression
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Molecular classification of high-grade, muscle-invasive urothelial carcinomas and the relationship with CTLA-4 and PD-L1 expression
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?